Jody L. Green
Research Subjects
Jody L. Green has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Richard C. Dart
Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO, United States
7 shared publications - Becki Bucher-Bartelson
Rocky Mountain Poison and Drug Center, 777 Bannock Street, Mailcode 0180, Denver, CO, 80204, USA
3 shared publications - Andrew Rosenblum
Institute for Treatment and Services Research, National Development and Research Institutes, New York, NY 10010, USA
2 shared publications G. Randall Bond
Faculty of Medicine, Hope Africa University, Bujumbura, Burundi
2 shared publications- Ian M. Paul
Pediatrics and Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA
2 shared publications Kate M. Reynolds
Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, Colorado
2 shared publications
Latest Publications
- 27 June 2017
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 26 (9) , 1044-1052
Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction‐Related Surveillance (RADARS) System Web Monitoring Program
This qualitative study summarizes information that individuals shared online about use of OxyContin following the August 2010 introduction of the abuse deterrent formulation (ADF).Purpose: The primary objective was to study online posts that endorsed continued use of OxyContin or a switch from OxyContin to another formulation of oxycodone or another substance altogether following the introduction of the ADF. A secondary objective was to determine whether posts revealed that the ADF led to cessation of OxyContin use.Methods: Data were collected with the Researched Abuse, Diversion, and Addiction‐Related Surveillance System Web Monitoring Program, an online surveillance system that collects and organizes posts about prescription drugs from social media websites, blogs, and forums from 3Q2009 to 4Q2014 using a commercially available web platform.Results: Posts were categorized by whether they conveyed a switch to drugs other than reformulated OxyContin or a continuation of reformulated OxyContin abuse. “Switch posts” primarily discussed switching to immediate‐release opioids. “Continue abusing” posts identified tampering strategies for alternate routes of administration, oral use, and continued use although post authors were generally unhappy with the experience. No reference to OxyContin cessation as a function of the introduction of the ADF was found; however, discontinued use was discussed.Conclusions: Web Monitoring data are useful for capturing cross sections of Internet conversation reflecting reactions to new drug formulations. These data support the notion that users will gravitate to non‐ADFs generally, and to immediate‐release non‐ADF opioid formulations, specifically, as long as these options remain on the market.
- 27 June 2017
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 26 (9) , 1044-1052
Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction‐Related Surveillance (RADARS) System Web Monitoring Program
This qualitative study summarizes information that individuals shared online about use of OxyContin following the August 2010 introduction of the abuse deterrent formulation (ADF).Purpose: The primary objective was to study online posts that endorsed continued use of OxyContin or a switch from OxyContin to another formulation of oxycodone or another substance altogether following the introduction of the ADF. A secondary objective was to determine whether posts revealed that the ADF led to cessation of OxyContin use.Methods: Data were collected with the Researched Abuse, Diversion, and Addiction‐Related Surveillance System Web Monitoring Program, an online surveillance system that collects and organizes posts about prescription drugs from social media websites, blogs, and forums from 3Q2009 to 4Q2014 using a commercially available web platform.Results: Posts were categorized by whether they conveyed a switch to drugs other than reformulated OxyContin or a continuation of reformulated OxyContin abuse. “Switch posts” primarily discussed switching to immediate‐release opioids. “Continue abusing” posts identified tampering strategies for alternate routes of administration, oral use, and continued use although post authors were generally unhappy with the experience. No reference to OxyContin cessation as a function of the introduction of the ADF was found; however, discontinued use was discussed.Conclusions: Web Monitoring data are useful for capturing cross sections of Internet conversation reflecting reactions to new drug formulations. These data support the notion that users will gravitate to non‐ADFs generally, and to immediate‐release non‐ADF opioid formulations, specifically, as long as these options remain on the market.
- Open Access
- 1 June 2017
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 139 (6) , e20163070
Safety Profile of Cough and Cold Medication Use in Pediatrics
BACKGROUND AND OBJECTIVES: The safety of cough and cold medication (CCM) use in children has been questioned. We describe the safety profile of CCMs in children <12 years of age from a multisystem surveillance program. METHODS: Cases with adverse events (AEs) after ingestion of at least 1 index CCM ingredient (brompheniramine, chlorpheniramine, dextromethorphan, diphenhydramine, doxylamine, guaifenesin, phenylephrine, and pseudoephedrine) in children 20% of all cases included tachycardia, somnolence, hallucinations, ataxia, mydriasis, and agitation. Twenty cases (0.6%) resulted in death; most were in children <2 years of age (70.0%) and none involved a therapeutic dose. The overall reported AE rate was 0.573 cases per 1 million units (ie, tablets, gelatin capsules, or liquid equivalent) sold (95% confidence interval, 0.553–0.593) or 1 case per 1.75 million units. CONCLUSIONS: The rate of AEs associated with CCMs in children was low. Fatalities occurred even less frequently. No fatality involved a therapeutic dose. Accidental unsupervised ingestions were the most common exposure types and single-ingredient, pediatric liquid formulations were the most commonly reported products. These characteristics present an opportunity for targeted prevention efforts.
- 1 June 2017
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 139 (6) , e20163070
Open AccessSafety Profile of Cough and Cold Medication Use in Pediatrics
BACKGROUND AND OBJECTIVES: The safety of cough and cold medication (CCM) use in children has been questioned. We describe the safety profile of CCMs in children <12 years of age from a multisystem surveillance program. METHODS: Cases with adverse events (AEs) after ingestion of at least 1 index CCM ingredient (brompheniramine, chlorpheniramine, dextromethorphan, diphenhydramine, doxylamine, guaifenesin, phenylephrine, and pseudoephedrine) in children 20% of all cases included tachycardia, somnolence, hallucinations, ataxia, mydriasis, and agitation. Twenty cases (0.6%) resulted in death; most were in children <2 years of age (70.0%) and none involved a therapeutic dose. The overall reported AE rate was 0.573 cases per 1 million units (ie, tablets, gelatin capsules, or liquid equivalent) sold (95% confidence interval, 0.553–0.593) or 1 case per 1.75 million units. CONCLUSIONS: The rate of AEs associated with CCMs in children was low. Fatalities occurred even less frequently. No fatality involved a therapeutic dose. Accidental unsupervised ingestions were the most common exposure types and single-ingredient, pediatric liquid formulations were the most commonly reported products. These characteristics present an opportunity for targeted prevention efforts.
- Open Access
- 1 June 2017
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 175, 140-145
Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration
- 1 June 2017
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 175, 140-145
Open AccessMedical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration
- Open Access
- 1 November 2016
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 168, 219-229
Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone
- 1 November 2016
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 168, 219-229
Open AccessSustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone
- 13 October 2016
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 55 (1) , 25-32
Adverse events associated with pediatric exposures to dextromethorphan
Study objective: Dextromethorphan is the most common over-the-counter (OTC) antitussive medication. We sought to characterize adverse events associated with dextromethorphan in children N = 420)] and autonomic symptoms [e.g., tachycardia (N = 224)] were the most common adverse events. Flushing and/or urticarial rash occurred in 18.1% of patients. Dystonia occurred in 5.4%. Conclusions: No fatalities were identified in this multifaceted surveillance program following a dextromethorphan-only ingestion. Adverse events were predominantly associated with overdose, most commonly affecting the central nervous and autonomic systems.
- 13 October 2016
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 55 (1) , 25-32
Adverse events associated with pediatric exposures to dextromethorphan
Study objective: Dextromethorphan is the most common over-the-counter (OTC) antitussive medication. We sought to characterize adverse events associated with dextromethorphan in children N = 420)] and autonomic symptoms [e.g., tachycardia (N = 224)] were the most common adverse events. Flushing and/or urticarial rash occurred in 18.1% of patients. Dystonia occurred in 5.4%. Conclusions: No fatalities were identified in this multifaceted surveillance program following a dextromethorphan-only ingestion. Adverse events were predominantly associated with overdose, most commonly affecting the central nervous and autonomic systems.
- 1 November 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 156, e83
An online national survey and the Crime Survey for England and Wales: Are the data comparable?
- 1 November 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 156, e83
An online national survey and the Crime Survey for England and Wales: Are the data comparable?
- Open Access
- 22 July 2014
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 15 (1) , 39
A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration
Acetaminophen administration for more than 4 days causes aminotransferase elevation in some subjects. The objective of this randomized, placebo-controlled trial is to describe the course of alanine aminotransferase (ALT) elevation in subjects administered 4 g/day of acetaminophen for at least 16 days.
- 22 July 2014
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 15 (1) , 39
Open AccessA randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration
Acetaminophen administration for more than 4 days causes aminotransferase elevation in some subjects. The objective of this randomized, placebo-controlled trial is to describe the course of alanine aminotransferase (ALT) elevation in subjects administered 4 g/day of acetaminophen for at least 16 days.
- Open Access
- 1 July 2014
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 47 (1) , 27-34
Abuse and diversion of buprenorphine sublingual tablets and film
- 1 July 2014
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 47 (1) , 27-34
Open AccessAbuse and diversion of buprenorphine sublingual tablets and film
- Open Access
- 1 May 2013
- Published by Western Journal of Emergency Medicine in Western Journal of Emergency Medicine
- Vol. 14 (3) , 218-226
Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis
Introduction: There are few reports summarizing the effectiveness of oral and intravenous (IV) acetylcysteine. We determined the proportion of acetaminophen poisoned patients who develop hepatotoxicity (serum transaminase > 1000 IU/L) when treated with oral and IV acetylcysteine. Methods: Studies were double abstracted by trained researchers. We determined the proportions of patients who developed hepatotoxicity for each route using a random effects model. Studies were further stratified by early and late treatment. Results: We screened 4,416 abstracts; 16 articles, including 5,164 patients, were included in the meta-analysis. The overall rate of hepatotoxicity for the oral and IV routes were 12.6% and 13.2%, respectively. Treatment delays are associated with a higher rate of hepatotoxicity. Conclusion: Studies report similar rates of hepatotoxicity for oral and IV acetylcysteine, but direct comparisons are lacking. While it is difficult to disentangle the effects of dose and duration from route, our findings suggest that the rates of hepatotoxicity are similar for oral and IV administration. [West J Emerg Med. 2013;14(3):218–226.]
- 1 May 2013
- Published by Western Journal of Emergency Medicine in Western Journal of Emergency Medicine
- Vol. 14 (3) , 218-226
Open AccessOral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis
Introduction: There are few reports summarizing the effectiveness of oral and intravenous (IV) acetylcysteine. We determined the proportion of acetaminophen poisoned patients who develop hepatotoxicity (serum transaminase > 1000 IU/L) when treated with oral and IV acetylcysteine. Methods: Studies were double abstracted by trained researchers. We determined the proportions of patients who developed hepatotoxicity for each route using a random effects model. Studies were further stratified by early and late treatment. Results: We screened 4,416 abstracts; 16 articles, including 5,164 patients, were included in the meta-analysis. The overall rate of hepatotoxicity for the oral and IV routes were 12.6% and 13.2%, respectively. Treatment delays are associated with a higher rate of hepatotoxicity. Conclusion: Studies report similar rates of hepatotoxicity for oral and IV acetylcysteine, but direct comparisons are lacking. While it is difficult to disentangle the effects of dose and duration from route, our findings suggest that the rates of hepatotoxicity are similar for oral and IV administration. [West J Emerg Med. 2013;14(3):218–226.]
- Open Access
- 14 March 2011
- Published by Springer Nature in BMC Gastroenterology
- Vol. 11 (1) , 20
Acetaminophen-cysteine adducts during therapeutic dosing and following overdose
Acetaminophen-cysteine adducts (APAP-CYS) are a specific biomarker of acetaminophen exposure. APAP-CYS concentrations have been described in the setting of acute overdose, and a concentration >1.1 nmol/ml has been suggested as a marker of hepatic injury from acetaminophen overdose in patients with an ALT >1000 IU/L. However, the concentrations of APAP-CYS during therapeutic dosing, in cases of acetaminophen toxicity from repeated dosing and in cases of hepatic injury from non-acetaminophen hepatotoxins have not been well characterized. The objective of this study is to describe APAP-CYS concentrations in these clinical settings as well as to further characterize the concentrations observed following acetaminophen overdose.
- 14 March 2011
- Published by Springer Nature in BMC Gastroenterology
- Vol. 11 (1) , 20
Open AccessAcetaminophen-cysteine adducts during therapeutic dosing and following overdose
Acetaminophen-cysteine adducts (APAP-CYS) are a specific biomarker of acetaminophen exposure. APAP-CYS concentrations have been described in the setting of acute overdose, and a concentration >1.1 nmol/ml has been suggested as a marker of hepatic injury from acetaminophen overdose in patients with an ALT >1000 IU/L. However, the concentrations of APAP-CYS during therapeutic dosing, in cases of acetaminophen toxicity from repeated dosing and in cases of hepatic injury from non-acetaminophen hepatotoxins have not been well characterized. The objective of this study is to describe APAP-CYS concentrations in these clinical settings as well as to further characterize the concentrations observed following acetaminophen overdose.